Key result
Tailored antithrombotic treatment, including potent P2Y12 inhibitors, is recommended for elderly patients with NSTE-ACS, carefully balancing ischemic benefits against increased bleeding risks.
Pharmacological treatment of NSTE-ACS in the elderly requires careful tailoring of antithrombotic therapy, particularly P2Y12 inhibitors, based on individual patient factors such as renal function and frailty.
May support tailored antithrombotic regimens in elderly NSTE-ACS; leaves open need for RCTs to define optimal P2Y12 use.
The increase in cardiovascular disease prevalence with ageing has been attributed to several age-related changes such as changes in the vascular wall elasticity, the coagulation and haemostatic system and endothelial dysfunction, among other causes. There is a 50% increased mortality risk per 10-year increase in age starting at 65 years old. Here, we aimed to discuss pharmacological treatment in acute coronary syndrome (ACS) without persistent ST segment elevation myocardial infarction in the elderly. The main aim of ACS treatment in elderly people is at preventing ischemia, myocardial damage and complications. A meta-analysis suggests that invasive revascularization therapy is probably most useful in older patients. Dual antiplatelet therapy is currently the standard of care post-ACS. Platelet P2Y12 inhibitors are among the most commonly used medications worldwide, due to their established benefits in the treatment and prevention of arterial thrombosis. The main recommendation is to tailor antithrombotic treatment, considering body weight, renal function (Class I, level C) and careful evaluation of life expectancy, comorbidities, risk/benefit profile, quality of life and frailty when invasive strategies are considered (Class IIa, level A) on top of the different recommendations given for a general non ST elevation ACS population. It is obvious that potent P2Y12 inhibitors will continue to play an important role in pharmacological treatment for elderly ACS patients in the future.
No takes yet. Share an insight, caveat, or question.
Usta et al. (2017) conducted a review in Non-ST segment elevation acute coronary syndrome (NSTE-ACS). Pharmacological treatment (P2Y12 inhibitors, anticoagulants) was evaluated. Tailored antithrombotic treatment, including potent P2Y12 inhibitors, is recommended for elderly patients with NSTE-ACS, carefully balancing ischemic benefits against increased bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: